LIGAND PHARMACEUTICALS INC (LGND)
Sector: Health Care
2026 Annual Meeting Analysis
LIGAND PHARMACEUTICALS INC · Meeting: June 5, 2026
Directors FOR
8
Directors AGAINST
0
Say on Pay
FOR
Auditor
AGAINST
Director Elections
Election of Directors
Ligand's 3-year price return of +199.4% outperforms the peer group median by +121.6 percentage points, well above the 65-point threshold needed to trigger a no vote in the strong-positive-TSR tier; Aryeh holds seats at Ligand, Orchestra BioMed, LifeCore Biomedical, and Anebulo — exactly four public boards, which is at the limit but does not exceed the four-board overboarding threshold.
As CEO and executive director, Davis is subject to the same TSR test as all other directors; Ligand's 3-year return of +199.4% outperforms the peer group median by +121.6 percentage points, far above the 65-point trigger threshold, so no TSR flag applies; Davis also holds two outside public board seats (Pelthos and Palvella), which equals but does not exceed the two-seat limit for sitting CEOs.
Gray has served since 2017 and the TSR trigger does not apply given Ligand's exceptional outperformance versus the peer group; she brings relevant scientific credentials and serves on the audit and nominating committees with no independence concerns.
Haas joined in June 2022 (just over three years ago) and the TSR trigger does not apply given Ligand's strong outperformance; his healthcare investment banking and CFO background provides directly relevant financial expertise for the audit and compensation committees.
Kozarich has served since 2003 and the TSR trigger does not apply given Ligand's substantial peer outperformance; his deep pharmaceutical R&D background is directly relevant to Ligand's royalty-focused business model.
LaMattina has served since 2011 and the TSR trigger does not apply given Ligand's exceptional 3-year outperformance; his 30-year Pfizer career including as President of Global R&D is highly relevant to evaluating biopharmaceutical royalty assets.
Sabba has served since 2008 and the TSR trigger does not apply given Ligand's outperformance; his background as a biopharma analyst and fund manager combined with his medical degree makes him well-suited as audit committee chair, and the proxy discloses he qualifies as an audit committee financial expert.
Zimmermann joined in September 2023, which is within the 24-month exemption window, so the TSR trigger does not apply to her; her regulatory affairs expertise at global biopharmaceutical companies is directly relevant to Ligand's business.
All eight director nominees receive a FOR vote. Ligand's 3-year stock price return of +199.4% outperforms the company-disclosed peer group median by +121.6 percentage points, which is well above the 65-point threshold required to trigger a no vote under the strong-positive-TSR tier, so no director is flagged on performance grounds. No overboarding violations (Jason Aryeh holds exactly four public seats, which is at but not over the limit; CEO Davis holds two outside public seats, which equals but does not exceed the CEO limit). No independence, attendance, or familial-relationship concerns were identified.
Say on Pay
✓ FORCEO
Todd C. Davis
Total Comp
$11,472,095
Prior Support
92.6%%
The prior say-on-pay vote received 92.6% support, well above the 70% threshold, signaling strong shareholder alignment with the pay program. The proxy discloses that 94% of CEO target total pay is variable or at-risk — heavily weighted toward stock options and performance-based restricted stock awards — which exceeds the policy's 50-60% minimum for variable pay and demonstrates a strong pay-for-performance structure. Ligand's 3-year total shareholder return of +199.4% substantially outperforms the XBI — SPDR S&P Biotech ETF benchmark by +130.6 percentage points, confirming that above-benchmark incentive pay is justified by actual shareholder outcomes; the company also discloses a Nasdaq-compliant clawback policy.
Auditor Ratification
✗ AGAINSTAuditor
Ernst & Young LLP
Tenure
10 yrs
Audit Fees
$1,461,576
Non-Audit Fees
$1,588,862
Ernst & Young's non-audit fees for fiscal year 2025 total approximately $1,588,862 (audit-related fees of $664,150 plus tax compliance fees of $803,987 plus all other fees of $120,725), which represents about 108.7% of the core audit fee of $1,461,576 — well above the 50% threshold that triggers a no vote under our policy. This high non-audit fee ratio raises concerns about auditor independence, as EY's consulting and tax work for Ligand has grown to exceed the size of the audit itself. Auditor tenure of approximately 10 years is below the 25-year concern threshold, and EY is a Big 4 firm appropriate for a $4.5B company, so neither of those checks is a concern.
Overall Assessment
The 2026 Ligand Pharmaceuticals annual meeting features four proposals: a director slate of eight nominees (all receiving FOR votes given exceptional TSR outperformance versus biotech peers), auditor ratification of Ernst & Young (receiving an AGAINST vote because non-audit fees exceed 108% of core audit fees, breaching the 50% independence threshold), an advisory say-on-pay vote (receiving a FOR vote given 94% at-risk CEO pay, strong shareholder returns, and 92.6% prior-year support), and an equity plan amendment (outside current policy scope). The most notable result is the AGAINST on auditor ratification driven by EY's substantial non-audit fee relationship with Ligand.
Compensation Peer Group
20 companies disclosed in 2026 proxy filing